APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripherally Acting Anti-Obesity Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Peripherally Acting Anti-Obesity Drug Industry Growth and Trends Forecast to 2032

20 December 2025101 pages

Choose your research edition.

Industry ResearchPeripherally Acting Anti-Obesity Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripherally Acting Anti-Obesity Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peripherally Acting Anti-Obesity Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripherally Acting Anti-Obesity Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripherally Acting Anti-Obesity Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peripherally Acting Anti-Obesity Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peripherally Acting Anti-Obesity Drug include Novo Nordisk A/S, Pfizer Inc., GlaxoSmithKline plc, Vivus LLC., Rhythm Pharmaceuticals, KVK Tech Inc., Gelesis Holdings, Currax Pharmaceuticals LLC and CHEPLAPHARM Arzneimittel GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Peripherally Acting Anti-Obesity Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Peripherally Acting Anti-Obesity Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peripherally Acting Anti-Obesity Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peripherally Acting Anti-Obesity Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Peripherally Acting Anti-Obesity Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Peripherally Acting Anti-Obesity Drug Market by Company

Novo Nordisk A/S

Pfizer Inc.

GlaxoSmithKline plc

Vivus LLC.

Rhythm Pharmaceuticals

KVK Tech Inc.

Gelesis Holdings

Currax Pharmaceuticals LLC

CHEPLAPHARM Arzneimittel GmbH

Boehringer Ingelheim International GmbH

Peripherally Acting Anti-Obesity Drug Segment by Type

Prescription Drugs

Non-prescription Drugs

Peripherally Acting Anti-Obesity Drug Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Peripherally Acting Anti-Obesity Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripherally Acting Anti-Obesity Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripherally Acting Anti-Obesity Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripherally Acting Anti-Obesity Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peripherally Acting Anti-Obesity Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Peripherally Acting Anti-Obesity Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Prescription Drugs Table 2. Major Company of Non-prescription Drugs Table 3. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 5. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Peripherally Acting Anti-Obesity Drug Price by Type (2021-2026) & (US$/unit) Table 9. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 10. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Peripherally Acting Anti-Obesity Drug Price by Type (2027-2032) & (US$/unit) Table 14. North America Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 15. North America Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 17. Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 21. Latin America Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Peripherally Acting Anti-Obesity Drug Industry Trends Table 25. Peripherally Acting Anti-Obesity Drug Industry Drivers Table 26. Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges Table 27. Peripherally Acting Anti-Obesity Drug Industry Restraints Table 28. Global Peripherally Acting Anti-Obesity Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Company (2021-2026) Table 30. Global Peripherally Acting Anti-Obesity Drug Sales by Company (2021-2026) & (k units) Table 31. Global Peripherally Acting Anti-Obesity Drug Sales Share by Company (2021-2026) Table 32. Global Peripherally Acting Anti-Obesity Drug Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Peripherally Acting Anti-Obesity Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Peripherally Acting Anti-Obesity Drug Major Company Production Sites and Headquarters Table 35. Global Peripherally Acting Anti-Obesity Drug Company, Product Type & Application Table 36. Global Peripherally Acting Anti-Obesity Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Peripherally Acting Anti-Obesity Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Peripherally Acting Anti-Obesity Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026) & (k units) Table 41. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032) & (k units) Table 46. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Peripherally Acting Anti-Obesity Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 52. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Peripherally Acting Anti-Obesity Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 57. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Peripherally Acting Anti-Obesity Drug Price by Application (2027-2032) & (US$/unit) Table 61. North America Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 62. North America Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 64. Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 68. Latin America Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Novo Nordisk A/S Company Information Table 72. Novo Nordisk A/S Business Overview Table 73. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio Table 75. Novo Nordisk A/S Recent Development Table 76. Pfizer Inc. Company Information Table 77. Pfizer Inc. Business Overview Table 78. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 80. Pfizer Inc. Recent Development Table 81. GlaxoSmithKline plc Company Information Table 82. GlaxoSmithKline plc Business Overview Table 83. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio Table 85. GlaxoSmithKline plc Recent Development Table 86. Vivus LLC. Company Information Table 87. Vivus LLC. Business Overview Table 88. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 90. Vivus LLC. Recent Development Table 91. Rhythm Pharmaceuticals Company Information Table 92. Rhythm Pharmaceuticals Business Overview Table 93. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio Table 95. Rhythm Pharmaceuticals Recent Development Table 96. KVK Tech Inc. Company Information Table 97. KVK Tech Inc. Business Overview Table 98. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 100. KVK Tech Inc. Recent Development Table 101. Gelesis Holdings Company Information Table 102. Gelesis Holdings Business Overview Table 103. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio Table 105. Gelesis Holdings Recent Development Table 106. Currax Pharmaceuticals LLC Company Information Table 107. Currax Pharmaceuticals LLC Business Overview Table 108. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio Table 110. Currax Pharmaceuticals LLC Recent Development Table 111. CHEPLAPHARM Arzneimittel GmbH Company Information Table 112. CHEPLAPHARM Arzneimittel GmbH Business Overview Table 113. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 115. CHEPLAPHARM Arzneimittel GmbH Recent Development Table 116. Boehringer Ingelheim International GmbH Company Information Table 117. Boehringer Ingelheim International GmbH Business Overview Table 118. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 120. Boehringer Ingelheim International GmbH Recent Development Table 121. North America Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 122. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 123. North America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2026) Table 124. North America Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032) & (k units) Table 125. North America Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Country (2027-2032) Table 126. North America Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Peripherally Acting Anti-Obesity Drug Market Share by Country (2021-2026) Table 129. North America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Peripherally Acting Anti-Obesity Drug Market Share Forecast by Country (2027-2032) Table 131. Europe Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 132. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 133. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2026) Table 134. Europe Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032) & (k units) Table 135. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Peripherally Acting Anti-Obesity Drug Market Share by Country (2021-2026) Table 139. Europe Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Peripherally Acting Anti-Obesity Drug Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 143. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032) & (k units) Table 145. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Share by Country (2021-2026) Table 149. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Share Forecast by Country (2027-2032) Table 151. Latin America Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. Latin America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 153. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2026) Table 154. Latin America Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032) & (k units) Table 155. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Peripherally Acting Anti-Obesity Drug Market Share by Country (2021-2026) Table 159. Latin America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Peripherally Acting Anti-Obesity Drug Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 163. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032) & (k units) Table 165. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Share by Country (2021-2026) Table 169. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Peripherally Acting Anti-Obesity Drug Distributors List Table 174. Peripherally Acting Anti-Obesity Drug Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Peripherally Acting Anti-Obesity Drug Image Figure 2. Global Peripherally Acting Anti-Obesity Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripherally Acting Anti-Obesity Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Peripherally Acting Anti-Obesity Drug Sales (2021-2032) & (k units) Figure 5. Prescription Drugs Image Figure 6. Global Prescription Drugs Sales YoY Growth (2021-2032) & (k units) Figure 7. Non-prescription Drugs Image Figure 8. Global Non-prescription Drugs Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Peripherally Acting Anti-Obesity Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Peripherally Acting Anti-Obesity Drug Market Share by Type 2025 VS 2032 Figure 11. North America Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Online Pharmacies Image Figure 24. Global Online Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 25. Hospital Pharmacies Image Figure 26. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 27. Retail Pharmacies Image Figure 28. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Peripherally Acting Anti-Obesity Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Peripherally Acting Anti-Obesity Drug Market Share by Application 2025 VS 2032 Figure 31. North America Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application in 2025 Figure 32. North America Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application in 2025 Figure 33. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application in 2025 Figure 34. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application in 2025 Figure 37. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share in Value by Application in 2025 Figure 41. North America Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Peripherally Acting Anti-Obesity Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Peripherally Acting Anti-Obesity Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Peripherally Acting Anti-Obesity Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Peripherally Acting Anti-Obesity Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Peripherally Acting Anti-Obesity Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Peripherally Acting Anti-Obesity Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Peripherally Acting Anti-Obesity Drug Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Peripherally Acting Anti-Obesity Drug Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • Non-prescription Drugs
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Vivus LLC.
  • Rhythm Pharmaceuticals
  • KVK Tech Inc.
  • Gelesis Holdings
  • Currax Pharmaceuticals LLC
  • CHEPLAPHARM Arzneimittel GmbH
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peripherally Acting Anti-Obesity Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Peripherally Acting Anti-Obesity Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Peripherally Acting Anti-Obesity Drug Market by Type
  6. 1.3.1 Prescription Drugs
  7. 1.3.2 Non-prescription Drugs
  8. 1.4 Global Peripherally Acting Anti-Obesity Drug Market Size by Type
  9. 1.4.1 Global Peripherally Acting Anti-Obesity Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Peripherally Acting Anti-Obesity Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Peripherally Acting Anti-Obesity Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Peripherally Acting Anti-Obesity Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Peripherally Acting Anti-Obesity Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Peripherally Acting Anti-Obesity Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Peripherally Acting Anti-Obesity Drug Industry Trends
  2. 2.2 Peripherally Acting Anti-Obesity Drug Industry Drivers
  3. 2.3 Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges
  4. 2.4 Peripherally Acting Anti-Obesity Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Peripherally Acting Anti-Obesity Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Peripherally Acting Anti-Obesity Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Peripherally Acting Anti-Obesity Drug Price (2021-2026)
  4. 3.4 Global Peripherally Acting Anti-Obesity Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peripherally Acting Anti-Obesity Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Peripherally Acting Anti-Obesity Drug Company, Product Type & Application
  7. 3.7 Global Peripherally Acting Anti-Obesity Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peripherally Acting Anti-Obesity Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peripherally Acting Anti-Obesity Drug Tier 1, Tier 2, and Tier 3
4 Peripherally Acting Anti-Obesity Drug Regional Status and Outlook
  1. 4.1 Global Peripherally Acting Anti-Obesity Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Peripherally Acting Anti-Obesity Drug Historic Market Size by Region
  3. 4.2.1 Global Peripherally Acting Anti-Obesity Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Peripherally Acting Anti-Obesity Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Peripherally Acting Anti-Obesity Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Peripherally Acting Anti-Obesity Drug Forecasted Market Size by Region
  7. 4.3.1 Global Peripherally Acting Anti-Obesity Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Peripherally Acting Anti-Obesity Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Peripherally Acting Anti-Obesity Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Peripherally Acting Anti-Obesity Drug by Application
  1. 5.1 Peripherally Acting Anti-Obesity Drug Market by Application
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Peripherally Acting Anti-Obesity Drug Market Size by Application
  6. 5.2.1 Global Peripherally Acting Anti-Obesity Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Peripherally Acting Anti-Obesity Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Peripherally Acting Anti-Obesity Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Peripherally Acting Anti-Obesity Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Peripherally Acting Anti-Obesity Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Peripherally Acting Anti-Obesity Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novo Nordisk A/S
  2. 6.1.1 Novo Nordisk A/S Company Information
  3. 6.1.2 Novo Nordisk A/S Business Overview
  4. 6.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio
  6. 6.1.5 Novo Nordisk A/S Recent Developments
  7. 6.2 Pfizer Inc.
  8. 6.2.1 Pfizer Inc. Company Information
  9. 6.2.2 Pfizer Inc. Business Overview
  10. 6.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  12. 6.2.5 Pfizer Inc. Recent Developments
  13. 6.3 GlaxoSmithKline plc
  14. 6.3.1 GlaxoSmithKline plc Company Information
  15. 6.3.2 GlaxoSmithKline plc Business Overview
  16. 6.3.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio
  18. 6.3.5 GlaxoSmithKline plc Recent Developments
  19. 6.4 Vivus LLC.
  20. 6.4.1 Vivus LLC. Company Information
  21. 6.4.2 Vivus LLC. Business Overview
  22. 6.4.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio
  24. 6.4.5 Vivus LLC. Recent Developments
  25. 6.5 Rhythm Pharmaceuticals
  26. 6.5.1 Rhythm Pharmaceuticals Company Information
  27. 6.5.2 Rhythm Pharmaceuticals Business Overview
  28. 6.5.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio
  30. 6.5.5 Rhythm Pharmaceuticals Recent Developments
  31. 6.6 KVK Tech Inc.
  32. 6.6.1 KVK Tech Inc. Company Information
  33. 6.6.2 KVK Tech Inc. Business Overview
  34. 6.6.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  36. 6.6.5 KVK Tech Inc. Recent Developments
  37. 6.7 Gelesis Holdings
  38. 6.7.1 Gelesis Holdings Company Information
  39. 6.7.2 Gelesis Holdings Business Overview
  40. 6.7.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio
  42. 6.7.5 Gelesis Holdings Recent Developments
  43. 6.8 Currax Pharmaceuticals LLC
  44. 6.8.1 Currax Pharmaceuticals LLC Company Information
  45. 6.8.2 Currax Pharmaceuticals LLC Business Overview
  46. 6.8.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio
  48. 6.8.5 Currax Pharmaceuticals LLC Recent Developments
  49. 6.9 CHEPLAPHARM Arzneimittel GmbH
  50. 6.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
  51. 6.9.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
  52. 6.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  54. 6.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments
  55. 6.10 Boehringer Ingelheim International GmbH
  56. 6.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 6.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 6.10.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  60. 6.10.5 Boehringer Ingelheim International GmbH Recent Developments
7 North America by Country
  1. 7.1 North America Peripherally Acting Anti-Obesity Drug Sales by Country
  2. 7.1.1 North America Peripherally Acting Anti-Obesity Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Peripherally Acting Anti-Obesity Drug Market Size by Country
  6. 7.2.1 North America Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Peripherally Acting Anti-Obesity Drug Sales by Country
  2. 8.1.1 Europe Peripherally Acting Anti-Obesity Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country
  6. 8.2.1 Europe Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Country
  2. 9.1.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Peripherally Acting Anti-Obesity Drug Sales by Country
  2. 10.1.1 South America Peripherally Acting Anti-Obesity Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Peripherally Acting Anti-Obesity Drug Market Size by Country
  6. 10.2.1 South America Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country
  2. 11.1.1 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Peripherally Acting Anti-Obesity Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Peripherally Acting Anti-Obesity Drug Value Chain Analysis
  2. 12.1.1 Peripherally Acting Anti-Obesity Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Peripherally Acting Anti-Obesity Drug Production Mode & Process
  7. 12.2 Peripherally Acting Anti-Obesity Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Peripherally Acting Anti-Obesity Drug Distributors
  10. 12.2.3 Peripherally Acting Anti-Obesity Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst